1.	Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: NCI, Other Protocol IDs: ID00-156, U10CA045809, P30CA016672, MDA-ID-00156, NCI-3410, CDR0000068897, 3410, NCT00024167
2.	Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: Other Protocol IDs: EORTC-30921, NCT00002503
3.	Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000491233, RTOG-0517, NCT00365105
4.	Phase I/II Study of Strontium-89 in the Treatment of Patients with Endocrine-Resistant Prostate Cancer with Painful Osseous Metastases Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: RTOG-8821, RTOG-88-21
5.	Phase II Randomized Study of Strontium-89 Alone, Estramustine/Vinblastine, and Strontium-89 plus Estramustine/Vinblastine in Androgen-Independent Prostate Cancer Metastatic to Bone (Summary Last Modified 02/1999) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MSKCC-95094, NCI-V96-0831
6.	Phase II Study of Sn-117m DTPA versus Strontium-89 in Patients with Painful Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 08/1999) Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DIATIDE-117-30, UCMC-97012201
7.	Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000360625, MDA-2003-0922, NCI-6459, 6459, NCT00081159
8.	A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: GUPPS2, NCT00156884